Another therapeutic strategy against rheumatoid arthritis is the neutralization of RANKL by specific monoclonal antibodies, which inhibits bone erosion’s progression by sequestering the main signaling molecule for osteoclast differentiation [53]. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.